Updated on 3 August 2012
Hope for cancer: Fermented wheat germ extract kills ovarian cancer cell
Singapore: A study published in the International Journal of Gynecological Cancer revealed that fermented wheat germ extract (FWGE) is effective in killing a wide range of ovarian cancer cells while simultaneously enhancing the cancer-fighting qualities of certain chemotherapy treatments.
Previous human clinical studies with FWGE have shown to significantly improve survival in melanoma, colorectal and oral cancer patients and lessen the side effects of chemotherapy in pediatric cancer patients.
Dr Patricia Judson, lead author of the study, gynecologic oncologist, and researcher at Moffitt Cancer Center, Tampa, said that, "The results of this study greatly exceeded my expectations. We have proven that Avemar (FWGE) has the ability to kill cancer cells in the petri dish, and that it enhances the effectiveness of chemotherapy treatments." Dr Judson expressed gratitude to the Merit Society of the Moffitt Cancer Center, which is Florida's only National Cancer Institute-designated comprehensive cancer center, for their funding.
The study, which had 13 contributors, reinforces and expands upon prior published research that has shown the potential of fermented wheat germ extract as a non-toxic, cancer-fighting agent. According to the study, the team's findings "confirm the value of Avemar - fermented wheat germ extract (FWGE) - as a natural product with anticancer properties that also enhances the activity of existing therapeutic agents. Furthermore, our findings provide substantial insights into the molecular basis of FWGE's effect on human cancer cells."
FWGE was invented by Hungarian biochemist Dr Mate Hidvegi, and has been the subject of more than 100 international experiments on three continents, and more than 30 peer-reviewed articles. Since inventing this all-natural nutraceutical in the early 1990s, Dr Hidvegi has worked to advance the therapeutic potential for patients diagnosed with a variety of cancers. Previous human clinical studies with Avemar have shown it can significantly improve survival in melanoma, colorectal and oral cancer patients and can lessen the side effects of chemotherapy in pediatric cancer patients.